Antihypertensive activity of alpha-methyldopa on a twice daily regimen in comparison to metoprolol. A multi-centre controlled clinical trial

Clin Exp Pharmacol Physiol Suppl. 1978:4:35-41.

Abstract

1. The antihypertensive effects of alpha-methyldopa and metoprolol have been compared in 110 patients (fifty-one males and fifty-nine females) with previously untreated essential hypertension (sixty-eight WHO stage 1 and forty-two WHO stage 2). 2. After 2 weeks of placebo, the patients were randomly allocated to treatment with either of the two drugs: alpha-methyldopa up to 500 mg b.i.d. and metroprolol up to 200 mg b.i.d. for 6 weeks. Periodical clinical, biochemical, haematological, radiological and electrocardiographical measurements were performed. 3. The average reduction in blood pressure produced by the two drugs was comparable. 4. In general, side-effects were few and tolerable: mainly bradycardia in the metoprolol group and dizziness and drowsiness in the alpha-methyldopa group. 5. The plasma renin activity was significantly reduced in the metoprolol but not in the alpha-methyldopa group.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Blood Pressure / drug effects
  • Clinical Trials as Topic
  • Female
  • Heart Rate / drug effects
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • Male
  • Methyldopa / adverse effects
  • Methyldopa / pharmacology
  • Methyldopa / therapeutic use*
  • Metoprolol / adverse effects
  • Metoprolol / pharmacology
  • Metoprolol / therapeutic use*
  • Middle Aged
  • Norepinephrine / urine
  • Placebos
  • Propanolamines / therapeutic use*
  • Renin / blood

Substances

  • Placebos
  • Propanolamines
  • Methyldopa
  • Renin
  • Metoprolol
  • Norepinephrine